PUBLICATIONS
The following publications, posters and citations are being provided for
corporation informational purposes. These publications are not intended
to promote the use of AMR101 which is not approved for marketing or sale.
Copyright to certain documents referenced below are held by their publishers.
Where possible, a link is provided to the publisher of the documents.
|
Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride
Levels (from the Multi-center, Placebo-controlled, Randomized, double-blind, 12-week study
with an open-label Extension [MARINE] Trial)
Am J Cardiol 2011; 108:682–690.
|
Credits:
|
Harold E. Bays, MD1,
Christie M. Ballantyne, MD2,
John J. Kastelein, MD, Ph.D.3,
Jonathan L. Isaacsohn, MD4,
Rene A. Braeckman, Ph.D.5,
Paresh N. Soni, MD, Ph.D.5
1Louisville Metabolic and Atherosclerosis Research Center, Louisville, Kentucky
2Baylor College of Medicine and Methodist DeBakey Heart and Vascular Center, Houston, Texas
3Academic Medical Center, Amsterdam, The Netherlands
4Medpace, Inc., Cincinnati, Ohio
5Amarin Pharma Inc., Mystic, Connecticut
|
|
|
AMR101,
a Pure-EPA Omega-3 Fatty Acid, Lowers Triglycerides in Patients with Very
High Triglycerides Without Raising LDL-C: The MARINE Study
|
Credits:
|
HE Bays1, CM Ballantyne2, JJ Kastelein3, E Stein4,
JL Isaacsohn4, RA Braeckman5, and PN Soni5
1Louisville, KY, USA
2Houston, TX, USA
3Amsterdam, The Netherlands
4Cincinnati, OH, USA
5Mystic, CT, USA
|
|
|
|
AMR101: Effects of a Pure EPA Omega-3 Fatty Acid on the Fatty Acid Profile in
Plasma and Red Blood Cells in Patients With Very High Triglycerides (Results
from the MARINE Study)
|
Credits:
|
Rene A. Braeckman, Ph.D.1; Mehar S. Manku, Ph.D.1;
Harold E. Bays, MD2; William G. Stirtan, Ph.D.1;
and Paresh N. Soni, MD, Ph.D.1
1Amarin Pharma Inc., Mystic, CT, USA
2Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA
|
|
This page last updated on September 8, 2011.
